학술논문
Renal Function in Patients with Thalassemia Major Receiving Exjade ® Dispersible Tablets and a New Film-coated Tablet Formulation of Deferasirox (Nanojade ® ).
Document Type
Academic Journal
Author
Falahati V; Clinical Research Development Center of Amir Kabir Hospital, Arak University of Medical Sciences, Arak, Iran.; Ghasemi A; Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Khomein, Iran.; Safari MR; Clinical Research Development Center of Amir Kabir Hospital, Arak University of Medical Sciences, Arak, Iran.; Ghaffari K; Department of Basic and Laboratory Sciences, Khomein University of Medical Sciences, Khomein, Iran.; Yousefichaijan P; Department of Pediatric Nephrology, Arak University of Medical Sciences, Arak, Iran.; Zamanian M; Department of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran.
Source
Publisher: Medknow Publications and Media Pvt. Ltd Country of Publication: India NLM ID: 101586897 Publication Model: eCollection Cited Medium: Print ISSN: 2277-9175 (Print) Linking ISSN: 22779175 NLM ISO Abbreviation: Adv Biomed Res Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2277-9175
Abstract
Background: In patients with β-thalassemia major (TM), one of the long-term complications of regular blood transfusion is renal dysfunction. The purpose of the current study was to evaluate the renal function in TM patients receiving Exjade ® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade ® ).
Materials and Methods: In this descriptive cross-sectional study, a total of 80 TM patients aged 11-48-year-old entered the study. Patients received 20-30 mg/kg/d (single dose) Exjade® (Exjade group, n = 40) and Nanojade® (Nanojade group, n = 40) orally. To evaluated renal function, serum creatinine (SCr ), estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), 24-h urine protein (U Pro ), U Ca /U Cr , spot U Pro /U Cr ratio, and serum ferritin were calculated at baseline and every 3 months to 9 months.
Results: There was no significant difference in SCr , BUN, eGFR, 24-h U Pro , U Pro /U Cr ratio, U Ca /U Cr ratio, and serum ferritin between groups at baseline and end of study ( P baseline > 0.05, P end of study > 0.05). There was no significant difference in proteinuria between groups at baseline and end of study ( P baseline > 0.05, P end of study > 0.05).
Conclusions: The proportion of SCr , BUN, eGFR, 24-h U Pro , U Pro /U Cr ratio, and U Ca /U Cr ratio was not significantly different in TM patients treated with Nanojade ® compared to patients' received Exjade ® . Nanojade ® had similar effects to Exjade ® , and therefore, the use of Nanojade ® is safe in TM patients and does not seem to be associated with increased renal failure, proteinuria, and hypercalciuria.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2022 Advanced Biomedical Research.)
Materials and Methods: In this descriptive cross-sectional study, a total of 80 TM patients aged 11-48-year-old entered the study. Patients received 20-30 mg/kg/d (single dose) Exjade® (Exjade group, n = 40) and Nanojade® (Nanojade group, n = 40) orally. To evaluated renal function, serum creatinine (S
Results: There was no significant difference in S
Conclusions: The proportion of S
Competing Interests: There are no conflicts of interest.
(Copyright: © 2022 Advanced Biomedical Research.)